A Digital Antimicrobial Stewardship Smartphone Application to Combat AMR: the AB-assistant
Launched by ANNELIES VERBON · Jan 3, 2019
Trial Information
Current as of August 11, 2025
Unknown status
Keywords
ClinConnect Summary
Rationale: Antimicrobials are an indispensable part of modern medicine. However, optimal prescription of these agents is becoming increasingly challenging because of the growing complexity of guidelines, and constantly changing epidemiology of infectious pathogens. Moreover, due to local variations in the prevalence of certain pathogens and antimicrobial resistance (AMR), antimicrobial choices need to be tailored to local epidemiology. Improvement of antimicrobial use, in particular prevention of overuse and suboptimal use of antimicrobials, through antimicrobial stewardship (AMS) programs ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Cluster level (wards):
- • • Medical and surgical wards.
- Physician level:
- • • All physicians involved in antibiotic prescribing decisions in the participating wards.
- Patient level:
- • • All patients hospitalized in the participating wards \>= 18 years of age to whom systemic antimicrobials are prescribed.
- Exclusion Criteria:
- Cluster level (wards):
- • Outpatient clinics
- • Psychiatry wards
- • ICU
- Physician level:
- • • None
- Patient level:
- • • None
- Treatment level:
- • • Surgical and medical prophylaxis.
About Annelies Verbon
Annelies Verbon is a dedicated clinical trial sponsor specializing in the advancement of innovative therapeutic solutions. With a focus on rigorous research methodologies and ethical standards, the organization aims to enhance patient care through the development of new treatments and interventions. Committed to fostering collaboration among stakeholders in the healthcare ecosystem, Annelies Verbon prioritizes transparency, scientific integrity, and patient safety in all clinical initiatives. Their mission is to contribute to the body of medical knowledge while ensuring that the needs and well-being of participants remain at the forefront of every study.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rotterdam, , Netherlands
Geneva, , Switzerland
Calgary, Alberta, Canada
Uppsala, , Sweden
Patients applied
Trial Officials
B D Huttner, MD, MS
Principal Investigator
University Hospital, Geneva
T Tängdén, MD, PhD
Principal Investigator
Uppsala University
John Conly, Prof. Dr.
Principal Investigator
University of Calgary Cumming School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials